In the update, analyst Rob Goldman discusses the Company’s elite new leadership team and how they help set the stage for future human clinical trials for diabetes and cancer.

“One of the untold stories regarding the recent transformation of PharmaCyte Biotech (OTCQB – PMCB) is that in the span of just over a year, CEO Kenneth L. Waggoner has significantly upgraded the quality of the Company’s leadership team, particularly with respect to the clinical research and execution side, which is a veritable “Who’s Who” in the global scientific and pharmaceutical community.”

“The Company recently announced that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard formerly served as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer. Having a former Big Pharma executive, especially one with M&A experience, is a huge “get” for a company of PharmaCyte Biotech’s size. Moreover, since many mid-stage biotechs end up as targets or actual acquisitions of Big Pharma, Mr. Liquard’s experience in understanding how to help build a company for growth and for possible sale are invaluable.”

Goldman points out, “This team is unique and elite on both the diabetes and cancer treatment categories. Virtually every member of PharmaCyte Biotech’s’s 16-member strong international Diabetes Consortium are noted experts in the field of diabetes research in Europe and Asia and their work has been published in top scientific journals.  Prof. Ann. M Simpson and her colleagues at the UTS developed the Melligen cell line, to which the Company owns the exclusive worldwide license. This line recently demonstrated in animal tests that it could reverse Type 1 diabetes.   When the Melligen cells are encapsulated using PharmaCyte Biotech signature platform technology, “Cell-in-a-Box®”, the world may see a break-through technology on how insulin-dependent diabetes is treated in humans.”

Goldman noted further that, “PharmaCyte Biotech’s officers and Dr. Matthias Lohr, head of the Scientific Advisory Board, also have impressive resumes in the scientific field. COO Dr. Gerald W. Crabtree served as project manager for the development of the anticancer agent, Taxol® while Dr. Löhr and Dr. Walter Günzburg, the Company’s Chief Scientific Officer, and Dr. Brian Salmons were instrumental in the development and clinical investigation of the earlier Cell-in-a-Box® clinical trials using live cell encapsulation technology for the treatment of advanced pancreatic cancer.”

“The group of scientists associated with the PharmaCyte Biotech on the oncology side boasts a past President of the American Association for Cancer Research who is also the leading authority on pancreatic cancer. In fact, Dr. Daniel Van Hoff, along with his team at Translational Drug Development (TD2), has conducted early clinical investigations of many of anti-cancer agents that have been approved by the FDA and that are in use today.  Considering that Translational Drug Development (TD2) has been conducting a series of preclinical studies using the Company’s flagship technology in recent months, it illustrates the merit and potentially huge value inherent in PharmaCyte Biotech’s technology.”

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission https://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. Since March 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $7500 for investment research services that includes the publication of a research report and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB – PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found atwww.PharmaCyteBiotech.com.

Goldman Small Cap Research
Rob Goldman, Analyst
+1-410-609-7100
rob@goldmanresearch.com